1.
Dermatol Nurs
; 15(3): 216-20, 224-5; quiz 226, 2003 Jun.
Article
in English
| MEDLINE
| ID: mdl-12875010
ABSTRACT
Alefacept (Amevive) is a recombinant, fully human fusion protein that selectively targets memory T cells that have been implicated in the pathogenesis of psoriasis. Alefacept is approved in the United States as a treatment for chronic plaque psoriasis. Alefacept is unique among treatments for moderate to severe psoriasis because of its selective therapeutic action, favorable safety profile, and ability to induce lengthy disease remissions.